EUCAST Technical Note on Aspergillus and amphotericin B, itraconazole, and posaconazole

Clinical Microbiology and Infection

Volumn 18, Issue 7, 2012, Pages

  Arendrup, Maiken C ^a   Cuenca Estrella, Manuel ^b   Lass Flörl, Cornelia ^c   Hope, William ^d   Arendrup, M C ^e   Hope, W W ^e   Florl C ^e   Cuenca Estrella, M ^e   Arikan, S ^e   Barchiesi, F ^e   Bille, J ^e   Chryssanthou, E ^e   Groll, A ^e   Gaustad, P ^e   Jarv H ^e   Klimko, N ^e   Lortholary, O ^e   Matos, T ^e   Moore, C ^e   Schmalreck, A ^e   Velegraki, A ^e   Verweij, P ^e   more..

^a STATENS SERUM INSTITUT   (Denmark)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e NONE

Author keywords

Amphotericin B; Aspergillus; Breakpoints; EUCAST Technical Note; Itraconazole; Posaconazole; Susceptibility testing

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ITRACONAZOLE; POSACONAZOLE;

ALLERGIC DISEASE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; DRUG BIOAVAILABILITY; DRUG MONITORING; EUROPE; INFORMATION PROCESSING; INVASIVE ASPERGILLOSIS; LUNG ASPERGILLOSIS; MEDICAL SOCIETY; MINIMUM INHIBITORY CONCENTRATION; POINT MUTATION; PRIORITY JOURNAL;

ASPERGILLUS;

EID: 84862629452     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03890.x     Document Type: Article

References (20)

1. Lass-Florl C, Griff K, Mayr A et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 2005; 131: 201-207.
2. Denning DW, Lee JY, Hostetler JS et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97: 135-144.
3. Glasmacher A, Hahn C, Leutner C et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999; 42: 443-451.
4. Lestner JM, Roberts SA, Moore CB, Howard SJ, Denning DW, Hope WW. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis 2009; 49: 928-930.
5. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009; 53: 24-34.
6. Boogaerts MA, Verhoef GE, Zachee P, Demuynck H, Verbist L, De Beule K. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989; 32 (suppl 1): 103-108.
7. Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, Warnock DW. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 1997; 40: 401-414.
8. Howard SJ, Cerar D, Anderson MJ et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009; 15: 1068-1076.
9. Howard SJ, Arendrup MC. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med Mycol 2011; 49 (suppl 1): 90-95.
10. Mortensen KL, Jensen RH, Johansen HK et al. Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance. J Clin Microbiol 2011; 49: 2243-2251.
11. Mellado E, Garcia-Effron G, Alcazar-Fuoli L et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 2007; 51: 1897-1904.
12. Verweij PE, Howard SJ, Melchers WJ, Denning DW. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat 2009; 12: 141-147.
13. Arendrup MC, Mavridou E, Mortensen KL et al. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS ONE 2010; 5: e10080.
14. Bueid A, Howard SJ, Moore CB et al. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother 2010; 65: 2116-2118.
15. Arendrup MC, Jensen RH, Grif K et al. In vivo emergence of Aspergillus terreus with reduced azole susceptibility and a Cyp51a M217I alteration. J Infect Dis 2012; in press.
16. Jang SH, Colangelo PM, Gobburu JV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 2010; 88: 115-119.
17. Howard SJ, Felton TW, Gomez-Lopez A, Hope WW. Posaconazole: the case for therapeutic drug monitoring. Ther Drug Monit 2012; 34: 72-76.
18. Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44: 2-12.
19. Howard SJ, Lestner JM, Sharp A et al. Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. J Infect Dis 2011; 203: 1324-1332.
20. Mavridou E, Bruggemann RJ, Melchers WJ, Mouton JW, Verweij PE. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother 2010; 54: 860-865.